Clinicians may use any of multiple oral diabetes agents to treat their diabetic patients. In their systematic review, Bolen
and colleagues summarize the evidence of benefits and harms of oral agents used for treating adults with type 2 diabetes.
They found that compared with newer, more expensive agents (thiazolidinediones, α-glucosidase inhibitors, and meglitinides),
older agents (second-generation sulfonylureas and metformin) have similar or superior effects on glycemic control, lipid levels,
blood pressure, and body weight. They found scant and inconclusive evidence about effects of agents on clinical end points,
such as cardiovascular disease.